Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks
×

Welcome to Allegro Ophthalmics
Accelerated Innovation. Needed Intervention.

Answering an Unmet Need in DME

Allegro’s lead investigational drug, Luminate®, contains a unique molecule that binds to integrins – a special class of cell surface receptors that plays diverse roles in cellular function. With a new method of action that works differently than existing therapies, Luminate® could help 50 percent of DME patients who don’t respond sufficiently to achieve functional vision.1

Allegro’s lead investigational drug Luminate® has been shown to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema.

Luminate®

  • Shown to significantly reduce the current burden of intravitreal injections
  • A viable option for patients with DME
  • Blocks the pathways that cause retinal damage in DME

Only Luminate® stabilizes the retina by suppressing multiple pathways that contribute to DME, helping patients achieve functional vision1

  • It has been proven to help patients achieve equivalent vision gain as anti-VEGF treatment, with HALF THE NUMBER OF TOTAL INJECTIONS1
Learn more about Allegro Ophthalmics here.



References: 1. Data on file.